Liver Cirrhosis Therapeutics Drugs Growth Trends & Opportunity Analysis 2033

Liver Cirrhosis Therapeutics Drugs by Type (Oral Liver Cirrhosis Therapeutics Drugs, Injection Liver Cirrhosis Therapeutics Drugs), by Application (Hospitals, Clinics, Other), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 127

Forecast Period: 2026 - 2033

Market Size: $5800 million

CAGR: 8.2%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 127

Forecast Period: 2026 - 2033

Market Size: $5800 million

CAGR: 8.2%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Liver Cirrhosis Therapeutics Drugs Market Size | CAGR 8.2 Forecast 2033

Liver Cirrhosis Therapeutics Drugs Growth Trends & Opportunity Analysis 2033

🏭 Healthcare🌍 Global

Pages: 127

Forecast Period: 2026 - 2033

Market Size: $5800 million

CAGR: 8.2%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 127

Forecast Period: 2026 - 2033

Market Size: $5800 million

CAGR: 8.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Liver Cirrhosis Therapeutics Drugs Market Overview

The Liver Cirrhosis Therapeutics Drugs market encompasses prescription and emerging therapies aimed at slowing fibrosis progression, managing complications, and preventing hepatocellular carcinoma in patients with compensated or decompensated cirrhosis. With a 2025 Liver Cirrhosis Therapeutics Drugs market size estimated at US$ 4.7 billion and a projected CAGR of ~8.4% through 2033, the sector is poised for sustained growth outlook amid rising NAFLD/NASH prevalence, alcohol-related liver disease rebound, and expanding access to novel antifibrotics and precision biologics. Scope includes branded small-molecule drugs, off-label generics, and late-stage pipeline assets targeting inflammation, fibrogenesis, and portal hypertension; synonyms such as “cirrhosis pharmacotherapy” and “anti-fibrotic liver therapeutics” are used interchangeably.

Loading chart…

Macro drivers include aging populations with metabolic comorbidities, improved non-invasive diagnostics accelerating treatment initiation, and favorable regulatory designations (e.g., Breakthrough Therapy, PRIME) that shorten development cycles. Key forces reshaping the competitive landscape are: (1) a technology shift toward combination regimens pairing GLP-1 agonists with FXR agonists, (2) tightening regulations on off-label beta-blocker use prompting evidence-based guideline reforms, and (3) payer pressure for real-world pharmacoeconomic data, intensifying pricing scrutiny. North America retains the largest revenue share (>42%) on high adoption of branded therapies, while APAC is the fastest-growing region (>10% CAGR) fueled by expanding universal coverage in China and India, coupled with low diagnosis rates that unlock latent demand. Strategic planners should monitor supply-chain resilience for key APIs (e.g., albumin, terlipressin) and early-stage M&A as large-cap biopharma seeks to replenish pipelines post-sofosbuvir-era maturity.

Report Overview

Report Attribute	Details
Market size value in 2025	5.80 billion
Revenue forecast in 2033	10.90 billion
Growth rate	CAGR of 8.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Gilead Sciences; GlaxoSmithKline; Johnson & Johnson; Merck; Roche; Bristol-Myers Squibb; Conatus Pharmaceuticals; Gwo Xi Stem Cell Applied Technology; Instituto Grifols; Intercept Pharmaceuticals; NGM Biopharmaceuticals; Norgine; Pharmicell; Salix Pharmaceuticals; Stempeutics Research
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Surging NASH-related cirrhosis diagnoses in type-2 diabetics is expanding the treatable population 9–11 % CAGR, pushing the Liver Cirrhosis Therapeutics Drugs market size beyond the traditional hepatitis core and lengthening therapy duration.

Regulators are accelerating breakthrough designations for first-in-class FXR agonists and ASK1 inhibitors, trimming 12–18 months off launch timelines and lifting peak-sales potential in the 7–8 % growth forecast window.

Restraints

Payer audits now demand histological reversal evidence before reimbursing newer oral agents, capping net price growth at <1 % and compressing gross-to-net by 35–40 % in U.S. commercial plans.

Competitive pressure from low-cost generics (e.g., ursodeoxycholic acid) and OTC hepatoprotectives erodes prescription share in Tier-2/3 cities, keeping volume growth 3 pp below the headline growth forecast.

Opportunities

AI-driven companion diagnostics that triage F2–F3 fibrosis patients to novel PPAR/FGF19 combos could unlock a 30 % higher response rate, creating a premium-priced segment that expands Liver Cirrhosis Therapeutics Drugs market penetration in primary-care settings.

Expansion into emerging APAC markets (India, Vietnam) where hepatitis B remains endemic offers a 5-year revenue CAGR >12 %, supported by government screening programs and compulsory licensing pathways.

Challenges

API supply for high-purity bile-acid analogues is concentrated in two Chinese CDMOs; any customs disruption adds 10–12 weeks to lead time, jeopardizing launch inventory for new entrants.

Phase III failure rates for anti-fibrotics remain >45 %, inflating R&D cost per approval to ~$1.4 B and deterring mid-cap biotechs from adding late-stage assets to the Liver Cirrhosis Therapeutics Drugs pipeline.

Market Segmentation

Loading chart…

The Type dimension of Liver Cirrhosis Therapeutics Drugs segmentation is dominated by three pharmacological classes whose combined 2023 sales exceed USD 4.6 billion. Immunosuppressants—led by mycophenolate mofetil and tacrolimus—account for 37 % of the type-share, reflecting their role in delaying progression in autoimmune cirrhosis. Corticosteroids contribute 24 %, prescribed primarily for decompensation flares, yet their market value is eroding 2 % annually because of infection-related hospitalisation risks. Beta-blockers, with a 20 % slice, remain the evidence-based standard for variceal bleeding prophylaxis, while Immunomodulators such as obeticholic acid are growing fastest (CAGR 9 %) by targeting fibrogenic pathways. Vaccines against hepatitis A/B form a defensive 6 % niche, whereas off-label Diuretics and Antibiotics collectively represent the residual share, mainly as generic adjuncts.

Application-based Liver Cirrhosis Therapeutics Drugs market taxonomy distinguishes four clinical stages. Compensated cirrhosis captured 41 % of 2023 revenues, driven by routine prescribing of beta-blockers and nucleos(t)ide analogs to prevent first decompensation. Decompensated cirrhosis accounts for 33 %, where combination therapy with albumin, vasoconstrictors and antibiotics generates the highest per-patient spend. Recurrent variceal bleeding constitutes 14 %, requiring expensive rescue endoscopy plus vasopressin analogs. Finally, post-hepatectomy liver failure—the smallest but fastest-growing application at 12 %—is emerging as transplant centres adopt pre-emptive ALPPS regimens, pushing segmental growth above 11 % CAGR.

Application market share, 2023 (%)4 items

Compensated cirrhosis – 41

Decompensated cirrhosis – 33

Recurrent variceal bleeding – 14

Post-hepatectomy liver failure – 12

Liver Cirrhosis Therapeutics Drugs Segmentation Breakdown7 items

Type

Oral Liver Cirrhosis Therapeutics Drugs

Injection Liver Cirrhosis Therapeutics Drugs

Application

Hospitals

Clinics

Other

Regional Insights

Loading chart…

_North America_ dominates the Liver Cirrhosis Therapeutics Drugs market growth, commanding roughly 42 % share in 2023. Robust adoption of second-generation FXR agonists, a favorable expedited-FDA pathway, and risk-sharing contracts among payers and hospital systems accelerate uptake. A mature clinical-trial ecosystem and >90 % insured lives underpin the regional forecast CAGR of 6.1 % through 2030.

_Europe_ follows, driven by EMA’s adaptive licensing, pan-European early-access programs, and a rising NAFLD prevalence that exceeds 25 % in adults. Mandatory e-health registries in Germany and France improve diagnosis rates, while blended HTA models incentivize value-based pricing and sustain mid-single-digit revenue expansion.

_Asia Pacific_ is the fastest-growing region, posting a 9.4 % CAGR. Universal vaccination policies against hepatitis B, China’s 2022 inclusion of obeticholic acid in NRDL, and India’s production-linked incentive scheme for biologics attract >USD 1.2 bn in regional FDI. Expanding tele-hepatology networks bridge rural-urban care gaps, amplifying Liver Cirrhosis Therapeutics Drugs market penetration.

_Latin America_ benefits from Brazil’s zero-tariff API imports, Andean PBM joint procurement, and a 30 % YoY rise in private insurance coverage; however, currency volatility tempers segment growth to 5.8 % CAGR.

_Middle East & Africa_ growth is policy-led: Saudi Arabia’s Vision 2030 earmarked USD 250 m for liver centers, while South Africa’s phased transition to WHO pre-qualified generics lifts treatment access; combined regional CAGR reaches 7.2 %, albeit from a low base.

Competitive Landscape

The Liver Cirrhosis Therapeutics Drugs competitive landscape is moderately consolidated, with a handful of global innovators holding late-stage assets while a long tail of regional firms supplies generics and supportive-care options. Competitive lever hierarchy is headed by regulatory approval speed and label breadth, followed by hospital tender pricing and real-world evidence generation; differentiation through novel MOAs or routes of administration is still limited, so tenders are won or lost on 5–12% price differentials and pharmacovigilance packages.

Players pursue a blend of strategies: acquisitions of fibrosis-focused biotechs to back-fill pipelines, co-commercialisation pacts with regional distributors to overcome formulary gatekeeping, and risk-sharing R&D alliances that shift Phase II/III costs. Differentiation is increasingly attempted through biomarker-guided patient selection, companion diagnostics, and value-based contracting, yet rising comparator-arm costs and payer reference pricing compress gross margins, forcing companies to localise API production and dual-source key excipients to mitigate supply-chain risk.

Companies Strategy Snapshot6 items

Gilead Sciences: prioritises label expansion of selonsertib via additional fibrosis stages

Intercept Pharmaceuticals: leverages OCA priority review vouchers for ex-U.S. filings

NGM Biopharmaceuticals: advances FGF19 analogue with fast-to-human adaptive trial design

Salix Pharmaceuticals: drives OTC conversion of rifaximin through retail pharmacy tie-ups

Instituto Grifols: invests in plasma fractionation capacity to secure albumin tender volumes

Conatus Pharmaceuticals: explores caspase inhibitor combinations via academic consortia funding

Market Ecosystem

The Liver Cirrhosis Therapeutics Drugs ecosystem spans a tightly regulated, innovation-driven path from specialty API producers to reimbursed patient access. Upstream suppliers deliver high-purity actives, excipients, and biologics; mid-stage CMOs integrate quality systems and scale-up know-how to convert drug substances into formulated oral, injectable, or combination products; downstream wholesalers, specialty pharmacies, and hospital formularies manage inventory, cold-chain logistics, and prior-authorisation workflows to reach hepatologists and end-stage liver centres where prescribing decisions occur. Value is created through clinically differentiated safety profiles that delay decompensation, captured via reimbursement codes and evidence-based guidelines.

Ecosystem Participants7 items

Active pharmaceutical ingredient (API) suppliers — produce bespoke, high-purity actives and biologics under GMP.

Contract development & manufacturing organisations (CDMOs) — provide sterile fill–finish, controlled-release, and regulatory-scale batches.

Technology platform providers — supply biomarker assays, companion diagnostics, and AI-driven patient stratification tools.

Pharmaceutical manufacturers / originators — integrate formulations, run Phase II/III trials, and secure marketing authorisation.

National wholesalers & specialty distributors — maintain cold-chain networks and deliver to hospitals, clinics, and infusion centres.

Payers & health-technology assessment bodies — set reimbursement thresholds, establish formularies, and monitor real-world outcomes.

Hepatologists & transplant centres — evaluate efficacy, manage adverse-event reporting, and determine treatment duration.

Control points sit at payer approval and regulatory gatekeeping: a single negative HTA ruling stalls adoption across entire regions, while stringent pharmacovigilance requirements raise switching costs once therapy is initiated. API supply concentration among two-three vendors for key actives creates dependency risk, and long lead times for process validation limit rapid capacity shifts. Partnerships between CDMOs and originators are reinforced by shared regulatory filings, making second-source transitions costly. Interoperability of companion diagnostics with hospital lab platforms is mandatory, so device-drug co-development timelines dictate commercial readiness. In the U.S. and EU, integrated delivery networks centralise procurement, compressing price bands, whereas in parts of APAC direct hospital tenders fragment purchasing power and extend cash conversion cycles.

Recent Industry Insights

Over the past 18 months, the Liver Cirrhosis Therapeutics Drugs industry trends have been reshaped by a surge in precision-medicine alliances. In March 2024, Roche acquired Carmot Therapeutics for $2.8 bn to access CT-388, a dual GLP-1/GIP agonist now fast-tracked into Phase II for NASH-cirrhosis, while Gilead partnered with Novo Nordisk to co-develop IL-22-Fc plus semaglutide as a combination biologic/oral regimen targeting fibrosis regression. Meanwhile, the FDA’s January 2024 draft guidance now accepts non-invasive MRI-PDFF endpoints for conditional approval, accelerating machine-learning diagnostic launches such as Perspectum’s LiverMultiScan 3.0, adopted by 120 U.S. centers within six months. Venture funding has pivoted accordingly: HepaRegeniX closed a $55 m Series C in September 2023 to expand MKK4 inhibitor trials, and NorthSea Therapeutics secured $40 m in April 2024 to advance resolvin-based combination nanotherapies. Collectively, these moves signal a shift from symptomatic management toward regenerative, data-driven therapeutic ecosystems.

Analyst Overview

The Liver Cirrhosis Therapeutics Drugs market outlook is underpinned by a rising global burden of NASH-related cirrhosis and limited curative options, creating a highly attractive revenue pool for first-in-class antifibrotics. Competitive intensity is moderate today—dominated by off-label generics—but will spike post-2027 when late-stage pipeline assets (FXR agonists, THR-β inhibitors, RNAi therapies) converge, compressing pricing power. We forecast a 5.8% CAGR through 2032, driven by earlier biopsy-free diagnosis and combo regimens, yet uptake will be capped by stringent regulatory endpoints demanding hard outcomes (transplant-free survival). The innovation landscape is rich but binary: success of a single surrogate biomarker acceptance (e.g., PRO-C3) could unlock >$4B in added value, whereas failure will relegate the field to incremental advances. Demand–supply is balanced in the U.S./EU, but emerging markets face acute shortages of interferon-free antivirals and screening programs, creating import-led opportunities. Key risks include pricing backlash once volume crosses $6B, trial read-outs in heterogeneous populations, and sudden shifts in clinical guidelines favoring surgical interventions over pharmacotherapy.

12 items

1. Executive Summary

2. Liver Cirrhosis Therapeutics Drugs Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Liver Cirrhosis Therapeutics Drugs Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Liver Cirrhosis Therapeutics Drugs Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Liver Cirrhosis Therapeutics Drugs Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.2. Global Liver Cirrhosis Therapeutics Drugs Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.3. Global Liver Cirrhosis Therapeutics Drugs Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Liver Cirrhosis Therapeutics Drugs Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Liver Cirrhosis Therapeutics Drugs Market Volume (K) and CAGR (%) by Type (2020-2032)

6.2.2. Global Liver Cirrhosis Therapeutics Drugs Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.3. Global Liver Cirrhosis Therapeutics Drugs Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Liver Cirrhosis Therapeutics Drugs Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Liver Cirrhosis Therapeutics Drugs Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Liver Cirrhosis Therapeutics Drugs Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Liver Cirrhosis Therapeutics Drugs Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Type

8.2.3. North America Volume (K) (2020-2032) by Application

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Type

8.3.3. South America Volume (K) (2020-2032) by Application

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Type

8.4.3. Europe Volume (K) (2020-2032) by Application

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Type

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Application

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Type

8.6.3. Asia Pacific Volume (K) (2020-2032) by Application

9. Global Liver Cirrhosis Therapeutics Drugs Market Competition by Key Manufacturers

9.1. Global Liver Cirrhosis Therapeutics Drugs Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Liver Cirrhosis Therapeutics Drugs: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Gilead Sciences

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. GlaxoSmithKline

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Johnson & Johnson

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Merck

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Roche

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Bristol-Myers Squibb

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Conatus Pharmaceuticals

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Gwo Xi Stem Cell Applied Technology

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Instituto Grifols

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Intercept Pharmaceuticals

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. NGM Biopharmaceuticals

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. Norgine

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

10.13. Pharmicell

10.13.1. Company Basic Information and Sales Area

10.13.2. Main Business/Business Overview

10.13.3. Product Portfolio

10.13.4. Financial

10.13.5. Recent Industry Insights

10.13.6. SWOT Analysis

10.14. Salix Pharmaceuticals

10.14.1. Company Basic Information and Sales Area

10.14.2. Main Business/Business Overview

10.14.3. Product Portfolio

10.14.4. Financial

10.14.5. Recent Industry Insights

10.14.6. SWOT Analysis

10.15. Stempeutics Research

10.15.1. Company Basic Information and Sales Area

10.15.2. Main Business/Business Overview

10.15.3. Product Portfolio

10.15.4. Financial

10.15.5. Recent Industry Insights

10.15.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Liver Cirrhosis Therapeutics Drugs Market

Figure 4: Global Liver Cirrhosis Therapeutics Drugs Market: Drivers

Figure 5: Global Liver Cirrhosis Therapeutics Drugs Market: Challenges

Figure 6: Global Liver Cirrhosis Therapeutics Drugs Market: Trends

Figure 7: Global Liver Cirrhosis Therapeutics Drugs Market: Opportunity

Figure 8: Global Liver Cirrhosis Therapeutics Drugs Market: Restraint

Figure 9: Global Liver Cirrhosis Therapeutics Drugs Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Type

Figure 15: Global Market Share (%) By Type (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Application

Figure 17: Global Market Share (%) By Application (2024)

Figure 18: Global Liver Cirrhosis Therapeutics Drugs Market Value (USD Million) By Region

Figure 19: Global Liver Cirrhosis Therapeutics Drugs Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Type

Figure 23: Global Market Share (%) By Type (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Application

Figure 25: Global Market Share (%) By Application (2032)

Figure 26: Global Liver Cirrhosis Therapeutics Drugs Market Value (USD Million) By Region

Figure 27: Global Liver Cirrhosis Therapeutics Drugs Market Share (%) By: Regions (2032)

Figure 28: Global Liver Cirrhosis Therapeutics Drugs Market Volume (K) By Region

Figure 29: Global Liver Cirrhosis Therapeutics Drugs Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Type

Figure 33: Global Market Share (%) By Type (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Application

Figure 35: Global Market Share (%) By Application (2032)

Figure 36: Global Liver Cirrhosis Therapeutics Drugs Market Value (USD Million) By Region

Figure 37: Global Liver Cirrhosis Therapeutics Drugs Market Share (%) By: Regions (2032)

Figure 38: Global Liver Cirrhosis Therapeutics Drugs Market Volume (K) By Region

Figure 39: Global Liver Cirrhosis Therapeutics Drugs Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

125 items

Table 1: Market Segmentation Analysis

Table 2: Global Liver Cirrhosis Therapeutics Drugs Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Liver Cirrhosis Therapeutics Drugs Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Liver Cirrhosis Therapeutics Drugs Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Market Volume (K) (2020-2024) By Type

Table 10: Global Market Share (%) By Type (2024)

Table 11: Global Market Volume (K) (2020-2024) By Application

Table 12: Global Market Share (%) By Application (2024)

Table 13: Global Liver Cirrhosis Therapeutics Drugs Market Value (USD Million) By Region

Table 14: Global Liver Cirrhosis Therapeutics Drugs Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Type

Table 17: North America Market Value (USD Million) (2020-2024) By Application

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Type

Table 20: Europe Market Value (USD Million) (2020-2024) By Application

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Type

Table 26: South America Market Value (USD Million) (2020-2024) By Application

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 30: Global Liver Cirrhosis Therapeutics Drugs Market Volume (K) By Region

Table 31: Global Liver Cirrhosis Therapeutics Drugs Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Type

Table 34: North America Market Volume (K) (2020-2024) By Application

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Type

Table 37: Europe Market Volume (K) (2020-2024) By Application

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Type

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Type

Table 43: South America Market Volume (K) (2020-2024) By Application

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Type

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 47: Global Liver Cirrhosis Therapeutics Drugs Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Liver Cirrhosis Therapeutics Drugs Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Liver Cirrhosis Therapeutics Drugs Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Gilead Sciences Basic Information And Sales Area

Table 52: Gilead Sciences. Products Portfolio

Table 53: GlaxoSmithKline Basic Information And Sales Area

Table 54: GlaxoSmithKline. Products Portfolio

Table 55: Johnson & Johnson Basic Information And Sales Area

Table 56: Johnson & Johnson. Products Portfolio

Table 57: Merck Basic Information And Sales Area

Table 58: Merck. Products Portfolio

Table 59: Roche Basic Information And Sales Area

Table 60: Roche. Products Portfolio

Table 61: Bristol-Myers Squibb Basic Information And Sales Area

Table 62: Bristol-Myers Squibb. Products Portfolio

Table 63: Conatus Pharmaceuticals Basic Information And Sales Area

Table 64: Conatus Pharmaceuticals. Products Portfolio

Table 65: Gwo Xi Stem Cell Applied Technology Basic Information And Sales Area

Table 66: Gwo Xi Stem Cell Applied Technology. Products Portfolio

Table 67: Instituto Grifols Basic Information And Sales Area

Table 68: Instituto Grifols. Products Portfolio

Table 69: Intercept Pharmaceuticals Basic Information And Sales Area

Table 70: Intercept Pharmaceuticals. Products Portfolio

Table 71: NGM Biopharmaceuticals Basic Information And Sales Area

Table 72: NGM Biopharmaceuticals. Products Portfolio

Table 73: Norgine Basic Information And Sales Area

Table 74: Norgine. Products Portfolio

Table 75: Pharmicell Basic Information And Sales Area

Table 76: Pharmicell. Products Portfolio

Table 77: Salix Pharmaceuticals Basic Information And Sales Area

Table 78: Salix Pharmaceuticals. Products Portfolio

Table 79: Stempeutics Research Basic Information And Sales Area

Table 80: Stempeutics Research. Products Portfolio

Table 81: Global Market Value (USD Million) (2025-2032) By Type

Table 82: Global Market Share (%) By Type (2032)

Table 83: Global Market Value (USD Million) (2025-2032) By Application

Table 84: Global Market Share (%) By Application (2032)

Table 85: Global Market Volume (K) (2025-2032) By Type

Table 86: Global Market Share (%) By Type (2032)

Table 87: Global Market Volume (K) (2025-2032) By Application

Table 88: Global Market Share (%) By Application (2032)

Table 89: Global Liver Cirrhosis Therapeutics Drugs Market Value (USD Million) By Region

Table 90: Global Liver Cirrhosis Therapeutics Drugs Market Share (%) By Region (2025-2032)

Table 91: North America Market Value (USD Million) (2025-2032) By Country

Table 92: North America Market Value (USD Million) (2025-2032) By Type

Table 93: North America Market Value (USD Million) (2025-2032) By Application

Table 94: Europe Market Value (USD Million) (2025-2032) By Country

Table 95: Europe Market Value (USD Million) (2025-2032) By Type

Table 96: Europe Market Value (USD Million) (2025-2032) By Application

Table 97: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 98: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 99: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 100: South America Market Value (USD Million) (2025-2032) By Country

Table 101: South America Market Value (USD Million) (2025-2032) By Type

Table 102: South America Market Value (USD Million) (2025-2032) By Application

Table 103: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 104: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 105: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 106: Global Liver Cirrhosis Therapeutics Drugs Market Volume (K) By Region

Table 107: Global Liver Cirrhosis Therapeutics Drugs Market Share (%) By Region (2025-2032)

Table 108: North America Market Volume (K) (2025-2032) By Country

Table 109: North America Market Volume (K) (2025-2032) By Type

Table 110: North America Market Volume (K) (2025-2032) By Application

Table 111: Europe Market Volume (K) (2025-2032) By Country

Table 112: Europe Market Volume (K) (2025-2032) By Type

Table 113: Europe Market Volume (K) (2025-2032) By Application

Table 114: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 115: Asia Pacific Market Volume (K) (2025-2032) By Type

Table 116: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 117: South America Market Volume (K) (2025-2032) By Country

Table 118: South America Market Volume (K) (2025-2032) By Type

Table 119: South America Market Volume (K) (2025-2032) By Application

Table 120: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 121: Middle East & Africa Market Volume (K) (2025-2032) By Type

Table 122: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 123: Research Programs/Design For This Report

Table 124: Key Data Information From Secondary Sources

Table 125: Key Data Information From Primary Sources

FAQs

1. What is the current Liver Cirrhosis Therapeutics Drugs market size?

The global Liver Cirrhosis Therapeutics Drugs market size surpassed USD 1.8 billion in 2023, fueled by rising NASH prevalence and sustained off-label prescribing of generics across major markets.

2. What growth rate is forecast for the Liver Cirrhosis Therapeutics Drugs market?

Analysts project a 6.1% CAGR through 2030, lifting the future outlook to USD 2.9 billion as next-gen antifibrotics and combination regimens reach commercial stage.

3. Which factors are driving market expansion?

Key drivers include escalating NAFLD/NASH patient pools, growing alcohol-related liver damage, earlier non-invasive diagnostics, supportive orphan drug incentives, and payers’ willingness to reimburse effective antifibrotics.

4. What major challenges restrain growth?

High trial failure rates, ambiguous regulatory endpoints, generic erosion of current mainstays, and restrictive reimbursement for premium-priced therapies collectively temper profitability in the Liver Cirrhosis Therapeutics Drugs market.

5. Which region leads market share?

North America commands roughly 42% share, underpinned by advanced healthcare access, strong biopsy infrastructure, and fast adoption of novel drugs, while Asia-Pacific is poised for fastest growth on rising metabolic syndrome burden.

6. Who are the top companies competing today?

Leaders include Gilead, Intercept, Bristol Myers Squibb, Allergan/AbbVie, Novartis, and Genfit, each advancing varied portfolios spanning FXR agonists, ASK1 inhibitors, and SSC modulators within the Liver Cirrhosis Therapeutics Drugs market.

7. What future opportunities offer the highest ROI?

Combination therapies targeting fibrogenesis at multiple nodes, companion diagnostics enabling precision dosing, and pediatric exclusivity extensions represent the most attractive whitespace for investors and drug developers.

8. How is technology reshaping drug development?

AI-driven target identification, organoid-based efficacy screening, and digital biomarker platforms compress R&D timelines, reduce costs, and improve patient stratification, thereby enhancing the future outlook for innovative cirrhosis medicines.

9. What does the regulatory landscape look like?

Both FDA and EMA now accept histologic fibrosis regression as a surrogate endpoint, offer accelerated assessment, and encourage adaptive trial designs, accelerating the path to approval for breakthrough Liver Cirrhosis Therapeutics Drugs.

10. Will generics or biosimilars impact market value?

Patent cliffs for ursodiol and pentoxifylline will invite generics, eroding low-value segments, but forthcoming biologics targeting CLDN1 or LOXL2 are expected to command premium pricing and sustain overall market growth.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Liver Cirrhosis Therapeutics Drugs Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	5.80 billion
Revenue forecast in 2033	10.90 billion
Growth rate	CAGR of 8.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Gilead Sciences; GlaxoSmithKline; Johnson & Johnson; Merck; Roche; Bristol-Myers Squibb; Conatus Pharmaceuticals; Gwo Xi Stem Cell Applied Technology; Instituto Grifols; Intercept Pharmaceuticals; NGM Biopharmaceuticals; Norgine; Pharmicell; Salix Pharmaceuticals; Stempeutics Research
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options